<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4831690</article-id><article-id pub-id-type="pmid">27078029</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0152724</article-id><article-id pub-id-type="publisher-id">PONE-D-15-28370</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pulmonology</subject><subj-group><subject>Asthma</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Mucus</subject><subj-group><subject>Sputum</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Mucus</subject><subj-group><subject>Sputum</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Mucus</subject><subj-group><subject>Sputum</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Mucus</subject><subj-group><subject>Sputum</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbiome</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genomics</subject><subj-group><subject>Microbial Genomics</subject><subj-group><subject>Microbiome</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial Genomics</subject><subj-group><subject>Microbiome</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Streptococcus</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Bacterial Pathogens</subject><subj-group><subject>Streptococcus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Bacterial Pathogens</subject><subj-group><subject>Streptococcus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Hematology</subject><subj-group><subject>Eosinophilia</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Bacterial Pathogens</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Bacterial Pathogens</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Mathematical and Statistical Techniques</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Multivariate Analysis</subject><subj-group><subject>Principal Component Analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics (Mathematics)</subject><subj-group><subject>Statistical Methods</subject><subj-group><subject>Multivariate Analysis</subject><subj-group><subject>Principal Component Analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Airway Microbiota in Severe Asthma and Relationship to Asthma Severity and Phenotypes </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">Airway Microbiota in Severe Asthma</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Qingling</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Cox</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liang</surname><given-names>Zhike</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Brinkmann</surname><given-names>Folke</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cardenas</surname><given-names>Paul A</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Duff</surname><given-names>Rachael</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bhavsar</surname><given-names>Pankaj</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cookson</surname><given-names>William</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>‡</sup></xref></contrib><contrib contrib-type="author"><name><surname>Moffatt</surname><given-names>Miriam</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>‡</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chung</surname><given-names>Kian Fan</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>‡</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>National Heart &amp; Lung Institute, Imperial College, London, United Kingdom</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Respiratory Biomedical Research Unit, Royal Brompton &amp; Harefield NHS Trust and Imperial College London, United Kingdom</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>State Key Laboratory of Respiratory Diseases, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Chalmers</surname><given-names>James D.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of Dundee, UNITED KINGDOM</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><text><SENT sid="1" pm="."><plain>Competing Interests: The authors have declared that no competing interests exist. </plain></SENT>
</text></p></fn><fn fn-type="con" id="contrib001"><p><text><SENT sid="2" pm="."><plain>Conceived and designed the experiments: WC MM KFC QZ. </plain></SENT>
<SENT sid="3" pm="."><plain>Performed the experiments: QZ MC ZL FB RD. </plain></SENT>
<SENT sid="4" pm="."><plain>Analyzed the data: MC WC MM QZ. </plain></SENT>
<SENT sid="5" pm="."><plain>Contributed reagents/materials/analysis tools: PC PB MC. </plain></SENT>
<SENT sid="6" pm="."><plain>Wrote the paper: KFC WC MM MC. </plain></SENT>
</text></p></fn><fn fn-type="other" id="econtrib001"><p><text><SENT sid="7" pm="."><plain>‡ These authors are joint senior authors on this work. </plain></SENT>
</text></p></fn><corresp id="cor001">* E-mail: <email>f.chung@imperial.ac.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>4</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><issue>4</issue><elocation-id>e0152724</elocation-id><history><date date-type="received"><day>30</day><month>6</month><year>2015</year></date><date date-type="accepted"><day>15</day><month>3</month><year>2016</year></date></history><permissions><copyright-statement>© 2016 Zhang et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Zhang et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0152724.pdf"/><abstract><sec id="sec001"><title><text><SENT sid="8" pm="."><plain>Background </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="9" pm="."><plain>The lower airways harbor a community of bacterial species which is altered in asthma. </plain></SENT>
</text></SecTag></p></sec><sec id="sec002"><title><text><SENT sid="10" pm="."><plain>Objectives </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="11" pm="."><plain>We examined whether the lower airway microbiota were related to measures of asthma severity. </plain></SENT>
</text></SecTag></p></sec><sec id="sec003"><title><text><SENT sid="12" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="13" pm="."><plain>We prospectively recruited 26 severe asthma, 18 non-severe asthma and 12 healthy subjects. </plain></SENT>
<SENT sid="14" pm="."><plain>DNA was extracted from induced sputum and PCR amplification of the V3-V5 region of bacterial 16S rRNA gene was performed. </plain></SENT>
</text></SecTag></p></sec><sec id="sec004"><title><text><SENT sid="15" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="16" pm="."><plain>We obtained 138,218 high quality sequences which were rarefied at 133 sequences/sample. </plain></SENT>
<SENT sid="17" pm="."><plain>Twenty OTUs had sequences ≥1% of total. </plain></SENT>
<SENT sid="18" pm="."><plain>There were marked differences in the distribution of Phyla between groups (P = 2.8x10-118). </plain></SENT>
<SENT sid="19" pm="."><plain>Bacteroidetes and Fusobacteria were reduced in non-severe and severe asthmatic groups. </plain></SENT>
<SENT sid="20" pm="."><plain>Proteobacteria were more common in non-severe asthmatics compared to controls (OR = 2.26; 95% CI = 1.94–2.64) and Firmicutes were increased in severe asthmatics compared to controls (OR = 2.15; 95%CI = 1.89–2.45). </plain></SENT>
<SENT sid="21" pm="."><plain>Streptococcal OTUs amongst the Firmicutes were associated with recent onset asthma, rhinosinusitis and sputum eosinophilia. </plain></SENT>
</text></SecTag></p></sec><sec id="sec005"><title><text><SENT sid="22" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="23" pm="."><plain>Sputum microbiota in severe asthma differs from healthy controls and non-severe asthmatics, and is characterized by the presence of Streptococcus spp with eosinophilia. </plain></SENT>
<SENT sid="24" pm="."><plain>Whether these organisms are causative for the pathophysiology of asthma remains to be determined. </plain></SENT>
</text></SecTag></p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000272</institution-id><institution>National Institute for Health Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Chung</surname><given-names>Kian Fan</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution>Asmarley Trust</institution></funding-source><principal-award-recipient><name><surname>Cookson</surname><given-names>William</given-names></name></principal-award-recipient></award-group><funding-statement>This work was supported by the NIHR Respiratory Biomedical Research Unit, Royal Brompton &amp; Harefield NHS Trust and Imperial College London, UK, and by the Asmarley Trust. WC and MF are Senior Investigators of the Wellcome Trust. KFC is an NIHR Senior Investigator. MC was supported by the Centre for Respiratory Infection Basic Science Fellowship. QZ and ZL were supported by the Guangzhou Respiratory Institute, and KFC is a Visiting Professor of the Guangzhou Respiratory Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="16"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>Data deposited at European Bioinformatics Institute: Accession number PRJEB11495.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>Data deposited at European Bioinformatics Institute: Accession number PRJEB11495.</p></notes></front><body><SecTag type="INTRO"><sec sec-type="intro" id="sec006"><title><text><SENT sid="25" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="26" pm="."><plain>Asthma is a common airway condition characterized by airway inflammation and intermittent episodes of airflow obstruction. </plain></SENT>
<SENT sid="27" pm="."><plain>That asthma is a syndrome consisting of different phenotypes has been recognised for a long time by clinicians [1]. </plain></SENT>
<SENT sid="28" pm="."><plain>Features such as the onset of asthma either in childhood or during later years, the presence of atopy, the effect of upper respiratory tract viral infections in inducing exacerbations of asthma, asthma induced by ingestion of aspirin or non-steroidal anti-inflammatory agents, and the concomitant presence of comorbidities such as rhinosinusitis or obesity, have been recognised as important clinical features that delineate certain asthma clusters [1, 2]. </plain></SENT>
<SENT sid="29" pm="."><plain>In addition, asthma may be categorised by the severity of chronic symptoms and by the occurrence of recurrent exacerbations of asthma despite treatment with maximal asthma medications including corticosteroids [3]. </plain></SENT>
<SENT sid="30" pm="."><plain>T-helper type 2 cells [Th2] are recognised as an important underlying mechanism of a specific asthma phenotype that is associated with high levels of circulating IgE and atopy, and eosinophilia [4, 5] The presence of eosinophils in sputum samples has been known to be associated with asthma and has been used to indicate a good therapeutic response to inhaled or oral corticosteroid therapy [6, 7]. </plain></SENT>
<SENT sid="31" pm="."><plain>On the other hand, those with neutrophilic inflammation have been linked to corticosteroid insensitivity and in some instances to bacterial infections and colonisation [8, 9]. </plain></SENT>
</text></p><p><text><SENT sid="32" pm="."><plain>Consistent epidemiological indications of the importance of the microbiome in asthma include the protection afforded by a rich microbial environment in early life [10, 11], observations that the bronchial tree contains a characteristic flora that is disturbed by the presence of pathogens in asthma [12–14], birth cohort studies showing that the presence of the same pathogens in throat swabs predicts the later development of asthma [15], recognition that these bacteria have consistently been associated with exacerbations of asthma [16], and evidence for the efficacy of antibiotics in the treatment of asthma and related syndromes [17–19]. </plain></SENT>
<SENT sid="33" pm="."><plain>In 27% of asthmatic patients presenting with an exacerbation of asthma, bacteria have been cultured from sputum samples, with Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Moraxella catarrhalis and Haemophilus influenzae being the most frequent bacteria isolated [20]. </plain></SENT>
<SENT sid="34" pm="."><plain>This spectrum of bacterial species was also isolated from induced sputum samples in 15% of patients during a stable period of asthma [8]. </plain></SENT>
<SENT sid="35" pm="."><plain>In addition, other species such as Mycoplasma pneumoniae and Chlamydophila pneumoniae have also been detected in patients with asthma [21]. </plain></SENT>
<SENT sid="36" pm="."><plain>Using a terminal restriction fragment length polymorphism profiling for bacterial community analysis, another study showed that the dominant species within the airway bacterial community in sputum samples from treatment-resistant asthma was Moraxella catarrhalis or a member of the Haemophilus or Streptococcus genera [22]. </plain></SENT>
</text></p><p><text><SENT sid="37" pm="."><plain>16S ribosomal RNA microarray rather than conventional culture techniques have been used recently to detect operational taxonomic units in lower airway epithelial samples. </plain></SENT>
<SENT sid="38" pm="."><plain>This technique has led to the detection of a microbiome in the lower airways of normal subjects that has hitherto been considered to be a sterile environment. </plain></SENT>
<SENT sid="39" pm="."><plain>In addition, airways of asthmatic subjects were reported to show a different microbiota compared to non-asthmatic subjects in terms of an increase in Proteobacteria particularly in Haemophilus, Moraxella, and Neisseria spp, with a reduction in Bacteroidetes [12]. </plain></SENT>
<SENT sid="40" pm="."><plain>Another study confirmed the increase in bacterial load particularly Proteobacteria in the lower airways of asthmatics, and the total bacterial burden and diversity correlated with bronchial hyperresponsiveness [13]. </plain></SENT>
<SENT sid="41" pm="."><plain>In induced sputum, a higher proportion of Proteobacteria with lesser content of Firmicutes and Actinobacteria in asthmatics compared to non-asthmatics was reported. </plain></SENT>
<SENT sid="42" pm="."><plain>By contrast, no differences in airway bacterial load were observed between subjects with asthma and normal control subjects as assessed by 16S rRNA copy number [23]. </plain></SENT>
<SENT sid="43" pm="."><plain>Neonates colonized in the hypopharyngeal region with S. pneumoniae, H. influenzae or M. catarrhalis, or with a combination of these organisms were at increased risk for recurrent wheeze and asthma early in life [15]. </plain></SENT>
<SENT sid="44" pm="."><plain>In neonates from the tropics, the increased prevalence of Haemophilus and Staphylococcus spp was proposed to contribute to wheezing illnesses [14]. </plain></SENT>
<SENT sid="45" pm="."><plain>Whether they contribute to asthma pathogenesis or whether they are altered as a consequence of asthma is at present unresolved [24]. </plain></SENT>
<SENT sid="46" pm="."><plain>However, the role of pathogens in causing disease and the actions of commensal bacteria in maintaining a healthy mucosa in the gut are well-recognised [25]. </plain></SENT>
</text></p><p><text><SENT sid="47" pm="."><plain>Previous studies of the airway microbiome showed that that the airways of moderate asthmatics contained an excess of Proteobacteria [12, 26] compared to normal controls, but asthma is heterogeneous in its clinical presentation and severity [3, 27] and it is possible that the airways of severe asthmatics have a different microbiota. </plain></SENT>
<SENT sid="48" pm="."><plain>In stable asthma patients with more severe disease, up to half had one or more bacteria cultured from sputum, with H. influenzae, P. aeruginosa and S. aureus being the most common [28]. </plain></SENT>
<SENT sid="49" pm="."><plain>It is therefore extremely valid and important to examine the respiratory microbiota in patients with severe asthma and determine whether the airway microbiota is altered compared to mild-moderate asthma as these differences could be important in determining both the pathophysiology and treatment of severe asthma. </plain></SENT>
<SENT sid="50" pm="."><plain>Therefore, we have determined whether patients with severe asthma have an altered microbiota compared to non-severe asthma measured by high throughput sequencing of 16S ribosomal RNA gene. </plain></SENT>
<SENT sid="51" pm="."><plain>More importantly, we also determined whether the altered microbiota were associated with any particular phenotype of asthma. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="sec007"><title><text><SENT sid="52" pm="."><plain>Methods </plain></SENT>
</text></title><p><text><SENT sid="53" pm="."><plain>This study was approved by the Ethics Committee of the Royal Brompton &amp; Harefield NHS Trust. </plain></SENT>
<SENT sid="54" pm="."><plain>All patients provided written informed consent to participate in this study by signing the consent form that was approved by the Ethics Committee of the Royal Brompton &amp; Harefield NHS Trust. </plain></SENT>
</text></p><sec id="sec008"><title><text><SENT sid="55" pm="."><plain>Subjects </plain></SENT>
</text></title><p><text><SENT sid="56" pm="."><plain>All non-asthmatic subjects were healthy volunteers without any disease with normal spirometric results (Table 1). </plain></SENT>
<SENT sid="57" pm="."><plain>Patients with severe asthma were recruited from the Severe Asthma clinic at the Royal Brompton Hospital, London, over a 6-month period. </plain></SENT>
<SENT sid="58" pm="."><plain>Patients with severe asthma needed either continuous or near-continuous oral corticosteroids, high-dose inhaled corticosteroids, or both to achieve a level of mild-to-moderate persistent asthma, and by 2 or more minor criteria [29]. </plain></SENT>
<SENT sid="59" pm="."><plain>All patients had been attending the clinic for at least 6 months and had undergone a Severe Asthma Protocol for confirmation of the diagnosis of severe asthma [30]. </plain></SENT>
<SENT sid="60" pm="."><plain>Patients with non-severe asthma had controlled asthma as defined by no daytime or nocturnal symptoms, no limitation of activities, minimal use of rescue medication while using up to 2,000 μg/d or equivalent of inhaled beclomethasone. </plain></SENT>
<SENT sid="61" pm="."><plain>Current smokers and ex-smokers of greater than 5 pack years were excluded. </plain></SENT>
<SENT sid="62" pm="."><plain>Patients with an exacerbation of asthma within the last 4 weeks or with a respiratory tract infection requiring antibiotic treatment within 6 weeks were excluded. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone.0152724.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0152724.t001</object-id><label>Table 1</label><caption><title><text><SENT sid="63" pm="."><plain>Characteristics of the subjects1. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone.0152724.t001g" xlink:href="pone.0152724.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"><text><SENT sid="64" pm="."><plain>Parameters </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="65" pm="."><plain>Healthy </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="66" pm="."><plain>Non-severe asthma </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="67" pm="."><plain>Severe asthma </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="68" pm="."><plain>Number </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="69" pm="."><plain>12 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="70" pm="."><plain>18 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="71" pm="."><plain>26 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="72" pm="."><plain>Age (years) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="73" pm="."><plain>35.4±10.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="74" pm="."><plain>45.2±16.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="75" pm="."><plain>47.9±10.9** </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="76" pm="."><plain>Gender (male:female) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="77" pm="."><plain>1:11 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>10:8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain>9:17 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="80" pm="."><plain>BMI (kg/m2) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain>24.5±5.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain>26.9±4.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="83" pm="."><plain>28.9±6.2* </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="84" pm="."><plain>Duration of asthma (years) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="85" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="86" pm="."><plain>29.7±19.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>22.6±16.5 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain>Ex-Smoker (n) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="90" pm="."><plain>3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>0 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>Rhinosinusitis (n) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="93" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain>4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain>8 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>Atopy 4 (n) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain>9 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>24 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="100" pm="."><plain>IgE IU/L2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="101" pm="."><plain>48.4 (26–80) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="102" pm="."><plain>112.2 (14–510)** </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="103" pm="."><plain>148.4 (2–4335)** ¶ </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="104" pm="."><plain>Daily prednisolone (mg.day-1) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="105" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="106" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="107" pm="."><plain>17.5±9.3 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="108" pm="."><plain>Inhaled corticosteroids3 (μg.day-1) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="109" pm="."><plain>0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain>1453±563 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain>2348±1140¶¶ </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>FEV1 (L) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>3.78±0.63 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="114" pm="."><plain>2.88±0.94 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain>2.25±0.60 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>FEV1 (% predicted) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>98.7±11.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain>87.0±15.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>76.7±15.9 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>FVC (L) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>4.69±0.59 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>3.89±0.98 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>3.25±0.74 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>FVC (% predicted) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>101.8±6.3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>99.8±14.7 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>92.0±11.7 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="128" pm="."><plain>Bronchodilator reversibility5 (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>Not done </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>14.4±10.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>17.9±12.1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>Blood eosinophils (per μl) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>0.10±0.0 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>0.28±0.17** </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>0.40±0.51 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>Sputum eosinophils (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>0.4±0.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>6.9±12.4 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>19.4±26.9** ¶ </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>Sputum neutrophils (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>49.6±27.6 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>45.7±24.8 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>45.0±27.4 </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p><text><SENT sid="144" pm="."><plain>1 Data shown as mean ± SD unless otherwise denoted. </plain></SENT>
</text></p></fn><fn id="t001fn002"><p><text><SENT sid="145" pm="."><plain>2 Data shown as geometric mean and range. </plain></SENT>
</text></p></fn><fn id="t001fn003"><p><text><SENT sid="146" pm="."><plain>3 Inhaled corticosteroid expressed as beclomethasone propionate equivalent dose </plain></SENT>
</text></p></fn><fn id="t001fn004"><p><text><SENT sid="147" pm="."><plain>4 Atopy defined as by the presence of positive skin-prick tests to at least one common aeroallergen. </plain></SENT>
</text></p></fn><fn id="t001fn005"><p><text><SENT sid="148" pm="."><plain>5 Bronchodilator reversibility calculated as postbronchodilator FEV1-prebronchodilator FEV1/prebronchodilator FEV1 x 100. </plain></SENT>
</text></p></fn><fn id="t001fn006"><p><text><SENT sid="149" pm="."><plain>BMI: Body mass index; FEV1: forced expiratory volume in one second; FVC: forced vital capacity. </plain></SENT>
</text></p></fn><fn id="t001fn007"><p><text><SENT sid="150" pm="."><plain>*P&lt;0.05 compared to healthy controls; </plain></SENT>
</text></p></fn><fn id="t001fn008"><p><text><SENT sid="151" pm="."><plain>**P&lt;0.01 compared to healthy controls; </plain></SENT>
</text></p></fn><fn id="t001fn009"><p><text><SENT sid="152" pm="."><plain>¶P&lt;0.05 compared to non-severe asthma; </plain></SENT>
</text></p></fn><fn id="t001fn010"><p><text><SENT sid="153" pm="."><plain>¶¶P&lt;0.01 compared to non-severe asthma. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="sec009"><title><text><SENT sid="154" pm="."><plain>Lung function and atopic status </plain></SENT>
</text></title><p><text><SENT sid="155" pm="."><plain>FEV1 and forced vital capacity (FVC) were measured using a spirometer (Erich Jaeger UK Ltd, Market Harborough, UK). </plain></SENT>
<SENT sid="156" pm="."><plain>Atopy was defined by the presence of positive skin-prick tests to at least one common aeroallergen including house dust mite, grass and tree pollen, cat dander, dog dander and Aspergillus. </plain></SENT>
</text></p></sec><sec id="sec010"><title><text><SENT sid="157" pm="."><plain>Sputum induction, cell count and microbiology </plain></SENT>
</text></title><p><text><SENT sid="158" pm="."><plain>Sputum was induced by inhalation of an aerosol of sterile 3% saline solution and subsequently increasing to 4% and 5% during 3 periods of 2 minutes each after the subject has had pre-treatment with inhaled salbutamol [31]. </plain></SENT>
<SENT sid="159" pm="."><plain>Particular care was taken to avoid contamination with saliva and post-nasal drip by instructing subjects to rinse orally with water and to blow their nose after each inhalation. </plain></SENT>
<SENT sid="160" pm="."><plain>Sputum samples were collected into sterile pots. </plain></SENT>
<SENT sid="161" pm="."><plain>Peak flow measurements were made after each inhalation. </plain></SENT>
<SENT sid="162" pm="."><plain>The procedure was not carried out if the subject brought up spontaneously sputum and if the baseline post-bronchodilator FEV1 was less than 60% predicted or less than 1.0 litre. </plain></SENT>
<SENT sid="163" pm="."><plain>If there was a fall in peak flow of 20% or more or if symptoms occurred during the procedure, the induction was stopped. </plain></SENT>
</text></p><p><text><SENT sid="164" pm="."><plain>For sputum bacteriological culture, an aliquot of induced sputum was selected using a positive displacement pipette and used for quantitative bacteriological culture [30]. </plain></SENT>
<SENT sid="165" pm="."><plain>Sputum plugs were selected and one portion was used to perform differential cell counts. </plain></SENT>
<SENT sid="166" pm="."><plain>To perform differential cell counts, di-thiothreitol was added to the sputum plug and mixed vigorously on a plate shaker to solubilize the sputum. </plain></SENT>
<SENT sid="167" pm="."><plain>Cytospins were then prepared, and differential cell counts obtained. </plain></SENT>
</text></p><p><text><SENT sid="168" pm="."><plain>For sputum 16S RNA assay, sputum plugs weighing more than 0.1g were selected and placed in a 1.5 ml sterile polypropylene centrifuge tube for DNA extraction. </plain></SENT>
</text></p></sec><sec id="sec011"><title><text><SENT sid="169" pm="."><plain>DNA extraction and PCR amplification and sequencing </plain></SENT>
</text></title><p><text><SENT sid="170" pm="."><plain>DNA extraction was performed using the QIAmp DNA Mini Kit extraction kit, modified to include a bead-beating step. </plain></SENT>
<SENT sid="171" pm="."><plain>The method proceeded as per manufacturer’s instruction until the end of the Proteinase K incubation, when the sample and lysis buffer were transferred to lysing matrix E bead-beating tubes (LME tubes; MP Biomedicals), and beaten in a Precellys bead-beater (Bertin Technologies) for 2 cycles of 30 seconds at 6800 rpm. </plain></SENT>
<SENT sid="172" pm="."><plain>DNA was eluted from the QIAmp columns in 40 μl of nuclease free water and stored at -80°C until further use. </plain></SENT>
</text></p><p><text><SENT sid="173" pm="."><plain>PCR amplification of the V3-V5 region of the 16S rRNA gene was performed using 1 μl of extracted DNA template. </plain></SENT>
<SENT sid="174" pm="."><plain>Reactions were performed in quadruplicate using primer pair 357F/926R (357F - CCTACGGGAGGCAGCAG, 926R - CCGTCAATTCMTTTRAGT), coupled with Roche 454 sequencing adaptors A (reverse primer) and B (forward primer) and a unique 12 base-pair barcode [32]. </plain></SENT>
<SENT sid="175" pm="."><plain>Replicates were combined and purified twice using Ampure XP (Beckman Coulter) bead purification, before quantification using the Quant iT kit (Life Technologies) and equimolar pooling. </plain></SENT>
<SENT sid="176" pm="."><plain>Thirty to fifty samples were pooled in each sequencing run on a Roche 454 Junior pyrosequencer, using the Lib-L kit and protocol (Roche Diagnostics Ltd). </plain></SENT>
</text></p></sec><sec id="sec012"><title><text><SENT sid="177" pm="."><plain>Data pre-processing </plain></SENT>
</text></title><p><text><SENT sid="178" pm="."><plain>Raw sequence files from each run were combined prior to denoising and chimera removal in QIIME [33] using Ampliconnoise and Perseus [34]. </plain></SENT>
<SENT sid="179" pm="."><plain>Operational taxonomic units (OTUs) at 97% identity were picked using UCLUST [35], the most abundant sequences in each OTU selected as representatives and classified using the RDP classifier [36] retrained with the Silva database version 111 [37]. </plain></SENT>
<SENT sid="180" pm="."><plain>Random resampling of the OTU table to 133 reads was performed in order to ensure equal sequence depth of each sample, whilst maintaining the ability to discriminate between samples, resulting in 3458 analysed. </plain></SENT>
</text></p></sec><sec id="sec013"><title><text><SENT sid="181" pm="."><plain>Data analysis </plain></SENT>
</text></title><p><text><SENT sid="182" pm="."><plain>Statistical analyses of phenotypic relationships were all carried out using IBM SPSS version 21. </plain></SENT>
<SENT sid="183" pm="."><plain>Asthma status was coded as non-asthmatic = 0, non-severe asthma = 1, and severe asthma = 2. </plain></SENT>
<SENT sid="184" pm="."><plain>The complex relationships between phenotypic variables were explored with Principal Components Analysis (PCA) in the FACTOR routine in SPSS. </plain></SENT>
<SENT sid="185" pm="."><plain>Missing values were replaced with the study mean for the relevant parameter. </plain></SENT>
<SENT sid="186" pm="."><plain>PCs with an eigenvalue &gt;1 were retained in the analysis, and a varimax rotation was applied. </plain></SENT>
<SENT sid="187" pm="."><plain>Bacterial counts were log-normalised after adding 1 to each count (to return a log value of 0 when the count was 0) before parametric analyses. </plain></SENT>
<SENT sid="188" pm="."><plain>Analyses of community diversity were carried out in the R statistical environment using the Phyloseq and Vegan packages. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="sec014"><title><text><SENT sid="189" pm="."><plain>Results </plain></SENT>
</text></title><sec id="sec015"><title><text><SENT sid="190" pm="."><plain>Patient characteristics </plain></SENT>
</text></title><p><text><SENT sid="191" pm="."><plain>The study population consisted of 56 subjects (12 normal subjects, 18 non-severe asthmatics and 26 severe asthmatics) (Table 1). </plain></SENT>
<SENT sid="192" pm="."><plain>Severe asthmatics had lower %FEV1 predicted (P&lt;0.05) and higher sputum eosinophil counts (P&lt;0.05), and higher BMI and atopy compared to non-severe asthma and normal subjects. </plain></SENT>
<SENT sid="193" pm="."><plain>15 of the 26 severe asthma patients were on daily oral prednisolone using a mean dose of 17.5 mg per day. </plain></SENT>
</text></p><p><text><SENT sid="194" pm="."><plain>Out of the 56 samples, potentially pathogenic bacteria were cultured from the sputum of 5 stable severe asthmatics (3 x Haemophilus influenzae, 1 x Moraxella catarrhalis and 1 x Staphylococcus aureus) and 5 stable non-severe asthmatics (1x, 2x and 2x respectively). </plain></SENT>
<SENT sid="195" pm="."><plain>No potentially pathogenic bacteria were cultured from the 12 healthy controls. </plain></SENT>
</text></p></sec><sec id="sec016"><title><text><SENT sid="196" pm="."><plain>PCA analysis of clinical variables </plain></SENT>
</text></title><p><text><SENT sid="197" pm="."><plain>PCA was carried out with the most important phenotypic variables (Table 2). </plain></SENT>
<SENT sid="198" pm="."><plain>In order to avoid over-fitting of the model, single variables were chosen to represent highly correlated related parameters. </plain></SENT>
<SENT sid="199" pm="."><plain>Four Principal Components (PC1-4) with eigenvalues &gt;1 and accounting for &gt;10% of the variance were identified (Table 2). </plain></SENT>
<SENT sid="200" pm="."><plain>Asthma status (from normal to severe asthma) was most strongly associated with the first two PCs, PC1 and PC2 (Table 2). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone.0152724.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0152724.t002</object-id><label>Table 2</label><caption><title><text><SENT sid="201" pm="."><plain>Principal Components Analysis of phenotypic variables. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone.0152724.t002g" xlink:href="pone.0152724.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1"><text><SENT sid="202" pm="."><plain>Component (% of total variance) </plain></SENT>
</text></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><text><SENT sid="203" pm="."><plain>1 (24%) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="204" pm="."><plain>2 (16%) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="205" pm="."><plain>3 (15%) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="206" pm="."><plain>4 (12%) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>Diagnosis </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>0.663 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="209" pm="."><plain>0.525 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="210" pm="."><plain>0.191 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain>0.273 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>FEV1 (% predicted) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>-0.117 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>-0.515 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>-0.227 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>-0.520 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain>Asthma duration </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>0.526 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>-0.113 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>0.567 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>Atopic status </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>0.773 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>0.351 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>0.213 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>Rhinosinusitis </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>0.138 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>0.619 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>0.271 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="229" pm="."><plain>Body mass index </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>0.525 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>Age </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>0.139 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>0.149 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>0.802 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>Inhaled corticosteroids </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>0.860 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>0.101 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>0.318 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>Salbutamol use </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>0.379 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>0.671 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>-0.174 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>Long-acting β-agonist </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>0.836 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>0.118 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>0.364 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>Oral corticosteroids </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>0.202 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>0.895 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>Sputum neutrophils </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>-0.750 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>0.247 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>Sputum eosinophils </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>-0.188 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>0.532 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>0.602 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>0.215 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>Blood eosinophils </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>-0.105 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>0.773 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>0.127 </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p><text><SENT sid="262" pm="."><plain>Principal Components accounting for &lt;10% variance and vector coefficients &lt; 0.1 are not shown. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="263" pm="."><plain>PC1 was typified by asthma of relatively long duration, atopy, a relatively high BMI, the use of inhaled steroids and long-acting β-agonist and a weak negative association with % sputum eosinophils. </plain></SENT>
<SENT sid="264" pm="."><plain>PC2 was associated with poor lung function, oral corticosteroid use and sputum eosinophilia. </plain></SENT>
<SENT sid="265" pm="."><plain>PC3 was typified by relatively recent onset, nasal disease, blood and sputum eosinophilia, and relatively fewer neutrophils in sputum. </plain></SENT>
<SENT sid="266" pm="."><plain>PC4 was characterised by the relatively increased age of the patients, poorer lung function and treatment with inhaled corticosteroids and long-acting β-agonist. </plain></SENT>
</text></p></sec><sec id="sec017"><title><text><SENT sid="267" pm="."><plain>Operational taxonomic units (OTUs) </plain></SENT>
</text></title><p><text><SENT sid="268" pm="."><plain>We obtained a total of 138,218 high quality sequences after de-noising and chimera removal. </plain></SENT>
<SENT sid="269" pm="."><plain>Following exclusion of singletons, 163 OTUs remained. </plain></SENT>
<SENT sid="270" pm="."><plain>Samples were rarefied at 133 sequences per sample for statistical analyses, such that a total of 7448 reads were used for subsequent analyses. </plain></SENT>
<SENT sid="271" pm="."><plain>Rarefaction with higher numbers of sequences reduced the numbers of subjects but did not change the principal findings of the study. </plain></SENT>
<SENT sid="272" pm="."><plain>Many of the OTUs were relatively uncommon, and we found 31 OTUs with numbers of sequences that were ≥0.5% of the total, 20 OTUs with sequences ≥1% of the total and 10 OTUs which made up ≥2% of the total. </plain></SENT>
<SENT sid="273" pm="."><plain>Because statistical power to detect associations to uncommon OTUs is limited, we confined downstream analyses to the 20 OTUs with sequences ≥1% of the total. </plain></SENT>
<SENT sid="274" pm="."><plain>We further excluded an OTU identified as Burkholderia (1.3% of total reads) because it was confined to three subjects and our kit controls indicated it to be a common contaminant. </plain></SENT>
</text></p><p><text><SENT sid="275" pm="."><plain>The most common phylum in the dataset was Firmicutes, containing 35.4% of sequences, followed by Bacteroidetes with 27.5% and Proteobacteria with 24.5%. </plain></SENT>
<SENT sid="276" pm="."><plain>There were marked differences in the distribution of Phyla between the three patient groups (χ2 = 530, 5 d.f.; P = 2.2x10-112) (Fig 1). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0152724.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0152724.g001</object-id><label>Fig 1</label><caption><title><text><SENT sid="277" pm="."><plain>Distribution of bacterial Phyla in healthy controls and non-severe and severe asthmatics defined by sequencing of the 16S rRNA gene. </plain></SENT>
</text></title><p><text><SENT sid="278" pm="."><plain>The distribution of bacterial phyla from 12 healthy subjects, 18 non-severe asthmatics and 26 severe asthmatics are shown. </plain></SENT>
<SENT sid="279" pm="."><plain>Compared to healthy controls, non-severe asthmatics showed a reduction in the prevalence of Bacteroidetes and Fusobacteria and an increase in Proteobacteria (all P&lt;10−10). </plain></SENT>
<SENT sid="280" pm="."><plain>Severe asthmatics showed an increase in Firmicutes compared to controls and non-severe asthmatics, together with reduction in Bacteroidetes and Fusobacteria compared to controls (all P&lt;10−10). </plain></SENT>
<SENT sid="281" pm="."><plain>The distribution of bacterial phyla is given in the accompanying lower Table as Operational Taxonomic Unit (OTU) counts with % total in brackets. </plain></SENT>
<SENT sid="282" pm="."><plain>The legend gives the odds ratios for each comparison. </plain></SENT>
<SENT sid="283" pm="."><plain>The overall χ2 for differences in phyla between phenotypic groups = 557.7 (P = 2.8x10-118). *OUT counts (% total). </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0152724.g001"/></fig></SecTag><p><text><SENT sid="284" pm="."><plain>Comparison between healthy controls and patients with non-severe asthma showed a reduction in the prevalence of Bacteroidetes, containing OTUs identified predominately as Gram-negative anaerobes such as Prevotella spp. </plain></SENT>
<SENT sid="285" pm="."><plain>(Odds Ratio (OR) = 0.62; 95% confidence interval (CI) = 0.54–0.71) and Fusobacteria (OR = 0.50; 95%CI = 0.40–0.63) (Fig 1), whereas Proteobacteria, containing potential respiratory pathogens such as, Neisseria and Moraxella spp., were more common in the patients with non-severe asthma compared to controls (OR = 2.26; 95%CI = 1.94–2.64). </plain></SENT>
</text></p><p><text><SENT sid="286" pm="."><plain>Bacteroidetes and Fusobacteria were also reduced in the severe asthma group compared to healthy controls (OR = 0.62; 95% CI = 0.54–0.70 and OR = 0.38; 95% CI = 0.31–0.48, respectively) (Fig 1). </plain></SENT>
<SENT sid="287" pm="."><plain>A minor increase in Proteobacteria was also seen in the severe asthmatics (OR = 1.21; 95% CI = 1.03–1.40) compared to non-asthmatic controls, but this was much less striking than the increase observed in Firmicutes, consisting predominately of streptococcal OTUs (OR = 2.15; 95% CI = 1.89–2.45). </plain></SENT>
<SENT sid="288" pm="."><plain>The increased presence of Firmicutes in severe asthma was also evident in comparison with the non-severe asthma group (OR = 2.15; 95% CI = 1.92–2.41) (Fig 1). </plain></SENT>
</text></p><p><text><SENT sid="289" pm="."><plain>These results are consistent with earlier studies that show a reduction in Bacteroidetes and an increase in Proteobacteria in adults and children with asthma [12, 14]. </plain></SENT>
<SENT sid="290" pm="."><plain>Our present results also indicate that the microbiota of severe asthmatics differs from that of non-severe asthmatics, and is characterized by an increase in the prevalence of Firmicutes rather than Proteobacteria. </plain></SENT>
</text></p><p><text><SENT sid="291" pm="."><plain>We next looked for differences closer to the species level, defined by particular OTUs. </plain></SENT>
<SENT sid="292" pm="."><plain>These two Streptococcus OTUs were positively correlated with asthma severity (Streptococcus_23, r = 0.41, P = 0.002; and Streptococcus_15, r = 0.35, P = 0.009), and one Prevotella OTU showed a negative correlation (Prevotella_292, r = 0.36, P = 0.007). </plain></SENT>
<SENT sid="293" pm="."><plain>Phylogenetic analysis of these sequences was not able to further differentiate the Streptococcus OTUs into individual species. Fig 2 shows the heat map of OTUs found in the sputum samples from asthmatic and non-asthmatic subjects. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0152724.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0152724.g002</object-id><label>Fig 2</label><caption><title><text><SENT sid="294" pm="."><plain>Heat map of operational taxonomic units (OTUs) found in the sputum of asthmatics and non-asthmatic subjects. </plain></SENT>
</text></title><p><text><SENT sid="295" pm="."><plain>The phylogenetic tree for the principal (&gt;1% of total) OTUs is shown at the left. </plain></SENT>
<SENT sid="296" pm="."><plain>On the right, increasing depth of colour indicates relative abundance of the OTU in an individual sample. </plain></SENT>
<SENT sid="297" pm="."><plain>Major phyla are shown between the phylogenetic tree and the heat map. </plain></SENT>
<SENT sid="298" pm="."><plain>Proteo = Proteobacteria; Fuso = Fusobacteria. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0152724.g002"/></fig></SecTag><p><text><SENT sid="299" pm="."><plain>Repeating the PCA and including the individual counts for these three OTUs showed that PC3 (relatively recent onset asthma with eosinophilia and nasal disease) was most strongly related with the presence of the two Streptococcus OTUs (Table 3). </plain></SENT>
<SENT sid="300" pm="."><plain>Weaker relationships were seen between Streptococcus_23 and PC1 (atopic disease treated with inhaled corticosteroid and long-acting β-agonist), and Streptococcus_155 and PC2 (severe asthma with sputum eosinophilia). </plain></SENT>
<SENT sid="301" pm="."><plain>PC2 was also associated with lower counts of Prevotella_292. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone.0152724.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0152724.t003</object-id><label>Table 3</label><caption><title><text><SENT sid="302" pm="."><plain>Principal Components Analysis of phenotypic variables including microbial associations. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone.0152724.t003g" xlink:href="pone.0152724.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1"><text><SENT sid="303" pm="."><plain>Component (% of total variance) </plain></SENT>
</text></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><text><SENT sid="304" pm="."><plain>1 (21%) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="305" pm="."><plain>2 (15%) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="306" pm="."><plain>3 (13%) </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="307" pm="."><plain>4 (12%) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="308" pm="."><plain>Diagnosis </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="309" pm="."><plain>0.661 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="310" pm="."><plain>0.533 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="311" pm="."><plain>0.259 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="312" pm="."><plain>0.239 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="313" pm="."><plain>FEV1 (% predicted) </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="314" pm="."><plain>-0.157 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="315" pm="."><plain>-0.471 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="316" pm="."><plain>-0.624 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="317" pm="."><plain>Asthma duration </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="318" pm="."><plain>0.668 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="319" pm="."><plain>-0.237 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="320" pm="."><plain>0.319 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="321" pm="."><plain>Atopic status </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="322" pm="."><plain>0.577 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="323" pm="."><plain>0.449 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="324" pm="."><plain>0.262 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="325" pm="."><plain>Rhinosinusitis </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="326" pm="."><plain>0.111 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="327" pm="."><plain>0.311 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="328" pm="."><plain>0.595 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="329" pm="."><plain>Body mass index </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="330" pm="."><plain>0.225 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="331" pm="."><plain>0.289 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="332" pm="."><plain>0.102 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="333" pm="."><plain>Age </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="334" pm="."><plain>0.388 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="335" pm="."><plain>0.661 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="336" pm="."><plain>Inhaled corticosteroids </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="337" pm="."><plain>0.934 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="338" pm="."><plain>0.173 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="339" pm="."><plain>Salbutamol use </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="340" pm="."><plain>0.362 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="341" pm="."><plain>0.693 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="342" pm="."><plain>-0.111 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="343" pm="."><plain>Long-acting β-agonist </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="344" pm="."><plain>0.923 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="345" pm="."><plain>0.175 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="346" pm="."><plain>Oral corticosteroids </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="347" pm="."><plain>0.897 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="348" pm="."><plain>0.207 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="349" pm="."><plain>Sputum neutrophils </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="350" pm="."><plain>0.176 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="351" pm="."><plain>-0.659 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="352" pm="."><plain>-0.243 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="353" pm="."><plain>Sputum eosinophils </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="354" pm="."><plain>-0.134 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="355" pm="."><plain>0.326 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="356" pm="."><plain>0.471 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="357" pm="."><plain>0.525 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="358" pm="."><plain>Blood eosinophils </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="359" pm="."><plain>0.558 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="360" pm="."><plain>0.487 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="361" pm="."><plain>Streptococcus_155 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="362" pm="."><plain>0.106 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="363" pm="."><plain>0.334 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="364" pm="."><plain>0.707 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="365" pm="."><plain>Streptococcus_23 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="366" pm="."><plain>0.342 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="367" pm="."><plain>0.671 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="368" pm="."><plain>Prevotella_292 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="369" pm="."><plain>-0.120 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="370" pm="."><plain>-0.404 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="371" pm="."><plain>-0.111 </plain></SENT>
</text></td><td align="char" char="." rowspan="1" colspan="1"><text><SENT sid="372" pm="."><plain>-0.145 </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p><text><SENT sid="373" pm="."><plain>Principal Components accounting for &lt;10% variance and vector coefficients &lt; 0.1 are not shown. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="374" pm="."><plain>Alpha diversity measures, species richness (the number of different OTUs), Pielou’s evenness (the skew or dominance of OTUs), Shannon and Inverse Simpson’s diversity indices, were calculated for each sample. </plain></SENT>
<SENT sid="375" pm="."><plain>There were no significant differences in alpha diversity between healthy, non-severe and severe asthmatics (Fig 3A). </plain></SENT>
<SENT sid="376" pm="."><plain>A Bray Curtis dissimilarity matrix was calculated and PERMANOVA (Adonis) used to demonstrate that community structure was significantly different between disease groups and they explained 6% of the variance in community structure (P = 0.008, Fig 3B). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0152724.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0152724.g003</object-id><label>Fig 3</label><caption><title><text><SENT sid="377" pm="."><plain>Diversity of microbial communities in healthy, non-severe and severe asthmatics. </plain></SENT>
</text></title><p><text><SENT sid="378" pm="."><plain>A. </plain></SENT>
<SENT sid="379" pm="."><plain>Boxplot of alpha diversity measures Species Richness and Shannon’s Diversity Index, which are not significantly different between groups. </plain></SENT>
<SENT sid="380" pm="."><plain>B Non metric multidimensional scaling of Bray Curtis distance split by group (stress 0.22). </plain></SENT>
<SENT sid="381" pm="."><plain>Here PERMANOVA (Adonis) indicates that community structure is significantly associated with asthma classification (P = 0.008) and this variable explains 6% of the variance. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0152724.g003"/></fig></SecTag></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="conclusions" id="sec018"><title><text><SENT sid="382" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="383" pm="."><plain>This analysis of the microbiota in patients with non-severe and severe asthma is one of the most substantial reported so far. </plain></SENT>
<SENT sid="384" pm="."><plain>We defined severe asthma as patients who remained uncontrolled despite taking sufficient amounts of asthma medication including corticosteroids, often as systemic doses as well as via the inhaled route. </plain></SENT>
<SENT sid="385" pm="."><plain>Even in this modest number of subjects, we found clusters of severe asthma such as those with poor lung function, oral corticosteroid use and sputum eosinophilia. </plain></SENT>
<SENT sid="386" pm="."><plain>We found that there were marked differences in the distribution of Phyla between groups. </plain></SENT>
<SENT sid="387" pm="."><plain>Our findings in patients with non-severe asthma are strongly consistent with earlier studies showing an increase in Proteobacteria and a reduction in non-pathogenic commensals when compared to controls [12, 14, 26]. </plain></SENT>
<SENT sid="388" pm="."><plain>We discovered equally distinctive changes in the severe asthma group. </plain></SENT>
<SENT sid="389" pm="."><plain>Bacteroidetes and Fusobacteria, representing non-pathogens were reduced in both non-severe and severe asthmatic groups compared to the healthy group, while Firmicutes were markedly increased in severe asthmatics. </plain></SENT>
<SENT sid="390" pm="."><plain>Amongst the Firmicutes, we also found that 2 Streptococcus spp., Streptococcus_23 and Streptococcus_155, were correlated with asthma severity. </plain></SENT>
<SENT sid="391" pm="."><plain>In addition, one OTU identified as Prevotella spp. showed negative correlation with asthma status. </plain></SENT>
<SENT sid="392" pm="."><plain>Though alpha diversity measures did not demonstrate a difference between asthma subgroups, there were small significant differences in the whole community structure as determined using an analysis of beta diversity. </plain></SENT>
<SENT sid="393" pm="."><plain>Thus, the airway microbiota in severe asthma is different from the non-severe asthma patient, which is in turn different from healthy controls. </plain></SENT>
<SENT sid="394" pm="."><plain>Furthermore, non-severe asthmatics demonstrated an increase in Proteobacteria relative to either healthy controls or severe asthmatics. </plain></SENT>
</text></p><p><text><SENT sid="395" pm="."><plain>In the study of Marri et al [38], who also used induced sputum samples from 10 non-asthmatic and 10 adults with asthma not taking inhaled or oral corticosteroid therapy at the time of the study, a greater abundance of Proteobacteria, particularly Haemophilus, and lower abundance of Firmicutes was reported. </plain></SENT>
<SENT sid="396" pm="."><plain>The increase in Proteobacteria confirmed the results of earlier studies [12, 13] using bronchial brushings from asthma patients who were on inhaled corticosteroid treatment, where Haemophilus was particularly seen to be increased, with the former study also reporting a decrease in Prevotella. </plain></SENT>
<SENT sid="397" pm="."><plain>Furthermore, our previous study [12], a group of asthmatic children with difficult-to-treat asthma on high dose inhaled corticosteroids, an increase in Proteobacteria/Haemophilus and Firmicutes/Staphylococcus or Streptococcus, and a decrease on Bacteroidetes/Prevotella were observed in bronchoalveolar lavage fluid samples. </plain></SENT>
<SENT sid="398" pm="."><plain>Our current data focused on an analysis of sputum samples from patients with severe asthma are consistent with the differences in phyla/genera previously reported between asthma and controls. </plain></SENT>
<SENT sid="399" pm="."><plain>Recently, using bronchial brushings from the lower airways, Huang et al. have reported that patients with severe asthma were significantly enriched in Actinobacteria compared to healthy control subjects or patients with mild-to-moderate asthma, with the largest differences seen in a member of the Klebsiella genus [39]. </plain></SENT>
<SENT sid="400" pm="."><plain>Whether the discrepancy between our findings and that of Huang et al. is due to differences in the region of the lung is unclear at present and would necessitate further investigation whereby intra-subject comparisons are done of bronchial brushing versus induced sputum. </plain></SENT>
</text></p><p><text><SENT sid="401" pm="."><plain>Asthma is a heterogeneous syndrome resulting from an interaction of different environmental factors [such as allergens, smoking and medications] with host factors to produce complex phenotypic manifestations [3, 27]. </plain></SENT>
<SENT sid="402" pm="."><plain>Phenotypic complexity can be simplified by statistical procedures such as principal component analysis [PCA] which identifies the most important variables and their correlations. </plain></SENT>
<SENT sid="403" pm="."><plain>PCA of the phenotypic data led to the definition of four main principal components. </plain></SENT>
<SENT sid="404" pm="."><plain>The first 2 clusters had characteristics of severe asthma [3] and were associated with the 3 bacterial species that were over- or under-represented in severe asthma. </plain></SENT>
<SENT sid="405" pm="."><plain>Thus, in Cluster PC2, patients on oral corticosteroid therapy with an atopic background, sputum eosinophilia and airflow obstruction were more likely to be associated with an increase of Streptococcus_155 and a decrease in Prevotella_292. </plain></SENT>
<SENT sid="406" pm="."><plain>On the other hand, Cluster PC1 also representing a severe group not on oral corticosteroids but on high dose inhaled corticosteroids and long-acting β-agonist, with a long duration of asthma and non-atopic background, was associated with an increase in both Streptococcus _23 and Streptococcus_155, and to some extent with a reduction in Prevotella_292. </plain></SENT>
<SENT sid="407" pm="."><plain>The greatest association with an increase in Streptococcus_155 and Streptococcus_23 was seen in Cluster PC3, characterised by both blood and sputum eosinophilia, but with a lower sputum neutrophil count, and nasal disease, with an increased likelihood of being on oral corticosteroids. </plain></SENT>
<SENT sid="408" pm="."><plain>These associations in distinct clusters of asthma may reflect the influence of specific elements of the microbiota on well-known characteristics of severe asthma such as eosinophilia, chronic airflow obstruction and corticosteroid insensitivity [40]. </plain></SENT>
<SENT sid="409" pm="."><plain>Alternatively, asthma treatments [such as corticosteroid or β-adrenergic agonist therapies] or the differences between asthma subtypes may select for particular microorganisms. </plain></SENT>
</text></p><p><text><SENT sid="410" pm="."><plain>Several confounding factors particularly in the severe asthmatic subjects need to be taken into consideration. </plain></SENT>
<SENT sid="411" pm="."><plain>First, the effect of asthma treatments on the airway microbiota remains unclear. </plain></SENT>
<SENT sid="412" pm="."><plain>In addition to potential unknown effects on bacterial persistence and growth, these medications may alter the innate immune response to bacteria that may in turn determine their pathogenicity. </plain></SENT>
<SENT sid="413" pm="."><plain>By definition, the patients with severe asthma that we studied were already on high doses of inhaled corticosteroids, often on oral corticosteroids. </plain></SENT>
<SENT sid="414" pm="."><plain>However, none were on antibiotic therapy or had been in the past 6 weeks, as this was one of the major entry criteria. </plain></SENT>
<SENT sid="415" pm="."><plain>The potential effect of corticosteroids on the lung microbiota is unclear, but comparing the microbiota data of Marri et al. [38] where patients with asthma not on inhaled corticosteroids were selected with those of Hilty et al. [12], there were no major differences that would indicate an effect of inhaled corticosteroids. </plain></SENT>
<SENT sid="416" pm="."><plain>On the other hand, in the small study of the lung microbiome in patients with moderate to severe COPD, the alterations in lung microbiome reported may have been accounted for by inhaled corticosteroid therapy [41]. </plain></SENT>
<SENT sid="417" pm="."><plain>The other important observation is that the gut microbiota has been reported to completely metabolise corticosteroids such as prednisolone, beclomethasone dipropionate and budesonide, but the effect of the airway microbiota in this context remains unknown [42]. </plain></SENT>
<SENT sid="418" pm="."><plain>The possibility that such an action by selected bacteria to preferentially metabolise corticosteroids could underlie corticosteroid insensitivity in severe asthma has not been tested. </plain></SENT>
</text></p><p><text><SENT sid="419" pm="."><plain>The significance of the changes in sputum microbiota that we observed in severe asthma suggests the need for further investigation. </plain></SENT>
<SENT sid="420" pm="."><plain>Since our patients with severe asthma may be classified as being corticosteroid-insensitive as demonstrated by studies on peripheral blood mononuclear cells or alveolar macrophages [43, 44], the recent study by Goleva and colleagues on bronchoalveolar lavage microbiota of patients defined as corticosteroid-resistant and corticosteroid insensitive is of interest [23]. </plain></SENT>
<SENT sid="421" pm="."><plain>In corticosteroid-resistant patients, they reported an increase in the proportion of sequences of microorganisms in the phyla Actinobacteria and Proteobacteria, and reduced sequences for the genera Prevotella and Veillonella, and Phylum Fusobacteria compared to normal control subjects [23]. </plain></SENT>
<SENT sid="422" pm="."><plain>Our data are partly in agreement with the reported reduction in Prevotella. </plain></SENT>
<SENT sid="423" pm="."><plain>Goleva et al further showed that the bacterium that was overexpressed in these patients, Haemophilus parainfluenzae, can directly induce corticosteroid resistance. </plain></SENT>
<SENT sid="424" pm="."><plain>In addition, Th-17 cells may be induced by bacterial infections and this has been implicated in corticosteroid insensitivity [45, 46]. </plain></SENT>
</text></p><p><text><SENT sid="425" pm="."><plain>Interestingly, the sputum culture results did not correlate with what was observed from the 16s rRNA analysis with positive cultures of Haemophilus influenzae, Moraxella catarrhalis and Staphylococcus aureus being most commonly observed in the asthmatic samples. </plain></SENT>
<SENT sid="426" pm="."><plain>This may not be surprising given the fact that sputum culture results will depend to a large extent on the media on which the bacteria are grown. </plain></SENT>
<SENT sid="427" pm="."><plain>On the other hand, DNA-based assays of microbiota does not allow one to determine the activity of members of the microbial community. </plain></SENT>
<SENT sid="428" pm="."><plain>A more comprehensive approach to culturing these bacteria is needed. </plain></SENT>
</text></p><p><text><SENT sid="429" pm="."><plain>One potential weakness of our study is the inevitable contamination of the upper airway microflora in the sputum samples. </plain></SENT>
<SENT sid="430" pm="."><plain>However, this contamination would have been similar for all subjects although the upper airway microbiota would also be influenced by the oral and dental state and the presence of comorbidities such as rhinosinusitis, laryngitis or gastrooesophageal reflux. </plain></SENT>
<SENT sid="431" pm="."><plain>The microbiota we found in this study is quite distinct from that described in various compartments of the upper airway and oral cavity such as saliva, nasopharynx and nose [47, 48]. </plain></SENT>
<SENT sid="432" pm="."><plain>Even in studies that have directly sampled the lower airways through a bronchoscope for brushings, biopsies or bronchoalveolar lavage fluid, there may have been contamination brought on by the passage of the bronchoscope through the upper airways prior to getting to the lower airways. </plain></SENT>
<SENT sid="433" pm="."><plain>At the other extreme, there is the suggestion that the bacteria found in the lower airway represents contamination of bacteria from the upper airways [49]. </plain></SENT>
<SENT sid="434" pm="."><plain>However, part of this microbiota is unique representing an adaptation towards proliferation in the lung environment [50]. </plain></SENT>
<SENT sid="435" pm="."><plain>It is important that such a study was performed in sputum samples because this is the most non-invasive way of obtaining lower airway samples relatively safely from patients, and will represent the only acceptable method of obtaining lower airway samples from all patients with asthma. </plain></SENT>
</text></p><p><text><SENT sid="436" pm="."><plain>While the 16S rRNA gene sequencing approach to define microbiota provides us with the bacterial members of the airway microbiota, it does not provide us with the fungi and viruses potentially present in the lower airways. </plain></SENT>
<SENT sid="437" pm="."><plain>Their potential contribution therefore is missed by using this approach. </plain></SENT>
<SENT sid="438" pm="."><plain>Another limitation of our cross-sectional study is that we are looking at a single time point and therefore are restricted in terms of the dynamic nature of the microbiota in severe asthma. </plain></SENT>
<SENT sid="439" pm="."><plain>Longitudinal studies would be advantageous but far from trivial when balancing the clinical care of patients with such severe disease and repeated invasive sampling. </plain></SENT>
<SENT sid="440" pm="."><plain>In addition, dormancy is common in microbial communities and activity of community members ideally requires a direct measure of activity such as RNA, protein or metabolic assays or serial sampling (requiring longitudinal studies) that we were unable to perform here. </plain></SENT>
<SENT sid="441" pm="."><plain>Finally, there are other alternative analytical methods available in the microbiome literature that could have been used in our study, but we have here restricted ourselves to the most commonly used methods in the absence of bench-marking studies. </plain></SENT>
<SENT sid="442" pm="."><plain>For example, there are many different and novel statistical tests available for comparing OTUs and other phylogenetic levels in microbiome studies, but no bench-marking. </plain></SENT>
<SENT sid="443" pm="."><plain>We have therefore resorted to use a well-established statistical test corrected for multiple testing. </plain></SENT>
</text></p><p><text><SENT sid="444" pm="."><plain>In summary, we have shown that in severe asthma, there is a distinct alteration of the sputum microbiota with a greater prominence of Firmicutes (including 2 Streptococcal OTUs, and a lower prominence of Bacteroidetes, particularly Prevotella spp. </plain></SENT>
<SENT sid="445" pm="."><plain>These bacterial OTUs were related to distinct components of the severe asthma syndrome, particularly those relating to the use of oral corticosteroids. </plain></SENT>
<SENT sid="446" pm="."><plain>Analysis of 16S rRNA gene sequences differentiates poorly between different streptococcal species, and further classification by typing additional polymorphic loci [18] as well as cultures of streptococcal isolates is desirable in future studies. </plain></SENT>
<SENT sid="447" pm="."><plain>In addition, the potential role of these streptococcal species in the pathogenesis of severe asthma will need further investigation. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="448" pm="."><plain>This work was supported by the NIHR Respiratory Biomedical Research Unit, Royal Brompton &amp; Harefield NHS Trust and Imperial College London, UK, and by the Asmarley Trust. </plain></SENT>
<SENT sid="449" pm="."><plain>WC and MF are Senior Investigators of the Wellcome Trust. </plain></SENT>
<SENT sid="450" pm="."><plain>KFC is an NIHR Senior Investigator. </plain></SENT>
<SENT sid="451" pm="."><plain>MC was supported by the Centre for Respiratory Infection Basic Science Fellowship. </plain></SENT>
<SENT sid="452" pm="."><plain>QZ and ZL were supported by the Guangzhou Respiratory Institute, and KFC is a Visiting Professor of the Guangzhou Respiratory Institute. </plain></SENT>
<SENT sid="453" pm="."><plain>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="pone.0152724.ref001"><text><SENT sid="454" pm="."><plain>1ChungKF. Defining phenotypes in asthma: a step towards personalized medicine. Drugs 2014; 74: 719–728. 10.1007/s40265-014-0213-9 <?supplied-pmid 24797157?>24797157 </plain></SENT>
</text></ref><ref id="pone.0152724.ref002"><text><SENT sid="455" pm="."><plain>2MooreWC, MeyersDA, WenzelSE, TeagueWG, LiH, LiX, et al Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181: 315–323. 10.1164/rccm.200906-0896OC <?supplied-pmid 19892860?>19892860 </plain></SENT>
</text></ref><ref id="pone.0152724.ref003"><text><SENT sid="456" pm="."><plain>3ChungKF, WenzelSE, BrozekJL, BushA, CastroM, SterkPJ, et al International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343–373. 10.1183/09031936.00202013 <?supplied-pmid 24337046?>24337046 </plain></SENT>
</text></ref><ref id="pone.0152724.ref004"><text><SENT sid="457" pm="."><plain>4WoodruffPG, ModrekB, ChoyDF, JiaG, AbbasAR, EllwangerA, et al T-helper type 2-driven inflammation defines major subphenotypes of asthma. AmJRespir Crit Care Med 2009; 180: 388–395. </plain></SENT>
</text></ref><ref id="pone.0152724.ref005"><text><SENT sid="458" pm="."><plain>5PetersMC, MekonnenZK, YuanS, BhaktaNR, WoodruffPG, FahyJV. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol 2014; 133: 388–394.e385 10.1016/j.jaci.2013.07.036 <?supplied-pmid 24075231?>24075231 </plain></SENT>
</text></ref><ref id="pone.0152724.ref006"><text><SENT sid="459" pm="."><plain>6BerryMA, ShawDE, GreenRH, BrightlingCE, WardlawAJ, PavordID. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. ClinExpAllergy 2005; 35: 1175–1179. </plain></SENT>
</text></ref><ref id="pone.0152724.ref007"><text><SENT sid="460" pm="."><plain>7DeykinA, LazarusSC, FahyJV, WechslerME, BousheyHA, ChinchilliVM, et al Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol 2005; 115: 720–727. <?supplied-pmid 15805990?>15805990 </plain></SENT>
</text></ref><ref id="pone.0152724.ref008"><text><SENT sid="461" pm="."><plain>8WoodLG, SimpsonJL, HansbroPM, GibsonPG. Potentially pathogenic bacteria cultured from the sputum of stable asthmatics are associated with increased 8-isoprostane and airway neutrophilia. Free radical research 2010; 44: 146–154. 10.3109/10715760903362576 <?supplied-pmid 19922242?>19922242 </plain></SENT>
</text></ref><ref id="pone.0152724.ref009"><text><SENT sid="462" pm="."><plain>9JatakanonA, MohamedJB, LimS, MaziakW, ChungKF, BarnesPJ. Neutrophils may contribute to the pathogenesis of airway inflammation in steroid dependent intractable asthma. Amer J Respir Crit Care Med 1998; 157: A875. </plain></SENT>
</text></ref><ref id="pone.0152724.ref010"><text><SENT sid="463" pm="."><plain>10EderW, EgeMJ, von MutiusE. The asthma epidemic. N Engl J Med 2006; 355: 2226–2235. <?supplied-pmid 17124020?>17124020 </plain></SENT>
</text></ref><ref id="pone.0152724.ref011"><text><SENT sid="464" pm="."><plain>11EgeMJ, MayerM, NormandAC, GenuneitJ, CooksonWO, Braun-FahrlanderC, et al Exposure to environmental microorganisms and childhood asthma. N Engl J Med 2011; 364: 701–709. 10.1056/NEJMoa1007302 <?supplied-pmid 21345099?>21345099 </plain></SENT>
</text></ref><ref id="pone.0152724.ref012"><text><SENT sid="465" pm="."><plain>12HiltyM, BurkeC, PedroH, CardenasP, BushA, BossleyC, et al Disordered microbial communities in asthmatic airways. PLOS one 2010; 5: e8578 10.1371/journal.pone.0008578 <?supplied-pmid 20052417?>20052417 </plain></SENT>
</text></ref><ref id="pone.0152724.ref013"><text><SENT sid="466" pm="."><plain>13HuangYJ, NelsonCE, BrodieEL, DesantisTZ, BaekMS, LiuJ, et al Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J Allergy Clin Immunol 2011; 127: 372–381.e371–373. 10.1016/j.jaci.2010.10.048 <?supplied-pmid 21194740?>21194740 </plain></SENT>
</text></ref><ref id="pone.0152724.ref014"><text><SENT sid="467" pm="."><plain>14CardenasPA, CooperPJ, CoxMJ, ChicoM, AriasC, MoffattMF, et al Upper airways microbiota in antibiotic-naive wheezing and healthy infants from the tropics of rural Ecuador. PLOS one 2012; 7: e46803 10.1371/journal.pone.0046803 <?supplied-pmid 23071640?>23071640 </plain></SENT>
</text></ref><ref id="pone.0152724.ref015"><text><SENT sid="468" pm="."><plain>15BisgaardH, HermansenMN, BuchvaldF, LolandL, HalkjaerLB, BonnelykkeK, et al Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med 2007; 357: 1487–1495. <?supplied-pmid 17928596?>17928596 </plain></SENT>
</text></ref><ref id="pone.0152724.ref016"><text><SENT sid="469" pm="."><plain>16KraftM. The role of bacterial infections in asthma. Clin Chest Med 2000; 21: 301–313. <?supplied-pmid 10907590?>10907590 </plain></SENT>
</text></ref><ref id="pone.0152724.ref017"><text><SENT sid="470" pm="."><plain>17JohnstonSL, BlasiF, BlackPN, MartinRJ, FarrellDJ, NiemanRB. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006; 354: 1589–1600. <?supplied-pmid 16611950?>16611950 </plain></SENT>
</text></ref><ref id="pone.0152724.ref018"><text><SENT sid="471" pm="."><plain>18SchwerkN, BrinkmannF, SoudahB, KabeschM, HansenG. Wheeze in preschool age is associated with pulmonary bacterial infection and resolves after antibiotic therapy. PLOS ONE 2011; 6: e27913 10.1371/journal.pone.0027913 <?supplied-pmid 22140482?>22140482 </plain></SENT>
</text></ref><ref id="pone.0152724.ref019"><text><SENT sid="472" pm="."><plain>19DonnellyD, CritchlowA, EverardML. Outcomes in children treated for persistent bacterial bronchitis. Thorax 2007; 62: 80–84. <?supplied-pmid 17105776?>17105776 </plain></SENT>
</text></ref><ref id="pone.0152724.ref020"><text><SENT sid="473" pm="."><plain>20CazzolaM, MateraMG, RossiF. Bronchial hyperresponsiveness and bacterial respiratory infections. Clinical therapeutics 1991; 13: 157–171. <?supplied-pmid 1709390?>1709390 </plain></SENT>
</text></ref><ref id="pone.0152724.ref021"><text><SENT sid="474" pm="."><plain>21KraftM, CassellGH, PakJ, MartinRJ. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest 2002; 121: 1782–1788. <?supplied-pmid 12065339?>12065339 </plain></SENT>
</text></ref><ref id="pone.0152724.ref022"><text><SENT sid="475" pm="."><plain>22GreenBJ, WiriyachaipornS, GraingeC, RogersGB, KehagiaV, LauL, et al Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment resistant severe asthma. PLOS one 2014; 9: e100645 10.1371/journal.pone.0100645 <?supplied-pmid 24955983?>24955983 </plain></SENT>
</text></ref><ref id="pone.0152724.ref023"><text><SENT sid="476" pm="."><plain>23GolevaE, JacksonLP, HarrisJK, RobertsonCE, SutherlandER, HallCF, et al The effects of airway microbiome on corticosteroid responsiveness in asthma. Am J Respir Crit Care Med 2013; 188: 1193–1201. 10.1164/rccm.201304-0775OC <?supplied-pmid 24024497?>24024497 </plain></SENT>
</text></ref><ref id="pone.0152724.ref024"><text><SENT sid="477" pm="."><plain>24HuangYJ, CharlsonES, CollmanRG, Colombini-HatchS, MartinezFD, SeniorRM. The role of the lung microbiome in health and disease. </plain></SENT>
<SENT sid="478" pm="."><plain>A National Heart, Lung, and Blood Institute workshop report. Am J Respir Crit Care Med 2013; 187: 1382–1387. 10.1164/rccm.201303-0488WS <?supplied-pmid 23614695?>23614695 </plain></SENT>
</text></ref><ref id="pone.0152724.ref025"><text><SENT sid="479" pm="."><plain>25MorthaA, ChudnovskiyA, HashimotoD, BogunovicM, SpencerSP, BelkaidY, et al Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science 2014; 343: 1249288 10.1126/science.1249288 <?supplied-pmid 24625929?>24625929 </plain></SENT>
</text></ref><ref id="pone.0152724.ref026"><text><SENT sid="480" pm="."><plain>26HuangYJ, BousheyHA. The microbiome in asthma. J Allergy Clin Immunol 2015; 135: 25–30. 10.1016/j.jaci.2014.11.011 <?supplied-pmid 25567040?>25567040 </plain></SENT>
</text></ref><ref id="pone.0152724.ref027"><text><SENT sid="481" pm="."><plain>27WenzelSE. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368: 804–813. <?supplied-pmid 16935691?>16935691 </plain></SENT>
</text></ref><ref id="pone.0152724.ref028"><text><SENT sid="482" pm="."><plain>28ZhangQ, IllingR, HuiCK, DowneyK, CarrD, StearnM, et al Bacteria in sputum of stable severe asthma and increased airway wall thickness. Respiratory research 2012; 13: 35 10.1186/1465-9921-13-35 <?supplied-pmid 22513083?>22513083 </plain></SENT>
</text></ref><ref id="pone.0152724.ref029"><text><SENT sid="483" pm="."><plain>29Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. </plain></SENT>
<SENT sid="484" pm="."><plain>American Thoracic Society. AmJ Respir Crit Care Med 2000; 162: 2341–2351.11112161 </plain></SENT>
</text></ref><ref id="pone.0152724.ref030"><text><SENT sid="485" pm="."><plain>30RobinsonDS, CampbellDA, DurhamSR, PfefferJ, BarnesPJ, ChungKF. Systematic assessment of difficult-to-treat asthma. EurRespir J 2003; 22: 478–483. </plain></SENT>
</text></ref><ref id="pone.0152724.ref031"><text><SENT sid="486" pm="."><plain>31PinI, GibsonPG, KolendowiczR, Girgis-GabardoA, DenburgJA, HargreaveFE, et al Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992; 47: 25–29. <?supplied-pmid 1539140?>1539140 </plain></SENT>
</text></ref><ref id="pone.0152724.ref032"><text><SENT sid="487" pm="."><plain>32FiererN, HamadyM, LauberCL, KnightR. The influence of sex, handedness, and washing on the diversity of hand surface bacteria. Proc Natl Acad Sci U S A 2008; 105: 17994–17999. 10.1073/pnas.0807920105 <?supplied-pmid 19004758?>19004758 </plain></SENT>
</text></ref><ref id="pone.0152724.ref033"><text><SENT sid="488" pm="."><plain>33CaporasoJG, KuczynskiJ, StombaughJ, BittingerK, BushmanFD, CostelloEK, et al QIIME allows analysis of high-throughput community sequencing data. Nature methods 2010; 7: 335–336. 10.1038/nmeth.f.303 <?supplied-pmid 20383131?>20383131 </plain></SENT>
</text></ref><ref id="pone.0152724.ref034"><text><SENT sid="489" pm="."><plain>34QuinceC, LanzenA, CurtisTP, DavenportRJ, HallN, HeadIM, et al Accurate determination of microbial diversity from 454 pyrosequencing data. Nature methods 2009; 6: 639–641. 10.1038/nmeth.1361 <?supplied-pmid 19668203?>19668203 </plain></SENT>
</text></ref><ref id="pone.0152724.ref035"><text><SENT sid="490" pm="."><plain>35EdgarRC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics (Oxford, England) 2010; 26: 2460–2461. </plain></SENT>
</text></ref><ref id="pone.0152724.ref036"><text><SENT sid="491" pm="."><plain>36WernerJJ, KorenO, HugenholtzP, DeSantisTZ, WaltersWA, CaporasoJG, et al Impact of training sets on classification of high-throughput bacterial 16s rRNA gene surveys. The ISME journal 2012; 6: 94–103. 10.1038/ismej.2011.82 <?supplied-pmid 21716311?>21716311 </plain></SENT>
</text></ref><ref id="pone.0152724.ref037"><text><SENT sid="492" pm="."><plain>37QuastC, PruesseE, YilmazP, GerkenJ, SchweerT, YarzaP, et al The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res 2013; 41: D590–596. 10.1093/nar/gks1219 <?supplied-pmid 23193283?>23193283 </plain></SENT>
</text></ref><ref id="pone.0152724.ref038"><text><SENT sid="493" pm="."><plain>38MarriPR, SternDA, WrightAL, BillheimerD, MartinezFD. Asthma-associated differences in microbial composition of induced sputum. J Allergy Clin Immunol 2013; 131: 346–352.e341–343. 10.1016/j.jaci.2012.11.013 <?supplied-pmid 23265859?>23265859 </plain></SENT>
</text></ref><ref id="pone.0152724.ref039"><text><SENT sid="494" pm="."><plain>39HuangYJ, NariyaS, HarrisJM, LynchSV, ChoyDF, ArronJR, et al The airway microbiome in patients with severe asthma: Associations with disease features and severity. J Allergy Clin Immunol 2015. </plain></SENT>
</text></ref><ref id="pone.0152724.ref040"><text><SENT sid="495" pm="."><plain>40ChungKF. New treatments for severe treatment-resistant asthma: targeting the right patient. Lancet Respiratory Medicine 2013; 1: 639–652. 10.1016/S2213-2600(13)70128-0 <?supplied-pmid 24461667?>24461667 </plain></SENT>
</text></ref><ref id="pone.0152724.ref041"><text><SENT sid="496" pm="."><plain>41PragmanAA, KimHB, ReillyCS, WendtC, IsaacsonRE. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLOS one 2012; 7: e47305 10.1371/journal.pone.0047305 <?supplied-pmid 23071781?>23071781 </plain></SENT>
</text></ref><ref id="pone.0152724.ref042"><text><SENT sid="497" pm="."><plain>42YadavV, GaisfordS, MerchantHA, BasitAW. Colonic bacterial metabolism of corticosteroids. International journal of pharmaceutics 2013; 457: 268–274. 10.1016/j.ijpharm.2013.09.007 <?supplied-pmid 24055438?>24055438 </plain></SENT>
</text></ref><ref id="pone.0152724.ref043"><text><SENT sid="498" pm="."><plain>43BhavsarP, HewM, KhorasaniN, TorregoA, BarnesPJ, AdcockI, et al Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma. Thorax 2008; 63: 784–790. 10.1136/thx.2007.090027 <?supplied-pmid 18492738?>18492738 </plain></SENT>
</text></ref><ref id="pone.0152724.ref044"><text><SENT sid="499" pm="."><plain>44HewM, BhavsarP, TorregoA, MeahS, KhorasaniN, BarnesPJ, et al Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. AmJRespir Crit Care Med 2006; 174: 134–141. </plain></SENT>
</text></ref><ref id="pone.0152724.ref045"><text><SENT sid="500" pm="."><plain>45McKinleyL, AlcornJF, PetersonA, DupontRB, KapadiaS, LogarA, et al TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 2008; 181: 4089–4097. <?supplied-pmid 18768865?>18768865 </plain></SENT>
</text></ref><ref id="pone.0152724.ref046"><text><SENT sid="501" pm="."><plain>46RameshR, KozhayaL, McKevittK, DjureticIM, CarlsonTJ, QuinteroMA, et al Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med 2014; 211: 89–104. 10.1084/jem.20130301 <?supplied-pmid 24395888?>24395888 </plain></SENT>
</text></ref><ref id="pone.0152724.ref047"><text><SENT sid="502" pm="."><plain>47LemonKP, Klepac-CerajV, SchifferHK, BrodieEL, LynchSV, KolterR. Comparative analyses of the bacterial microbiota of the human nostril and oropharynx. mBio 2010; 1. </plain></SENT>
</text></ref><ref id="pone.0152724.ref048"><text><SENT sid="503" pm="."><plain>48XuX, HeJ, XueJ, WangY, LiK, ZhangK, et al Oral cavity contains distinct niches with dynamic microbial communities. Environmental microbiology 2014. </plain></SENT>
</text></ref><ref id="pone.0152724.ref049"><text><SENT sid="504" pm="."><plain>49CharlsonES, BittingerK, HaasAR, FitzgeraldAS, FrankI, YadavA, et al Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med 2011; 184: 957–963. 10.1164/rccm.201104-0655OC <?supplied-pmid 21680950?>21680950 </plain></SENT>
</text></ref><ref id="pone.0152724.ref050"><text><SENT sid="505" pm="."><plain>50MorrisA, BeckJM, SchlossPD, CampbellTB, CrothersK, CurtisJL, et al Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am J Respir Crit Care Med 2013; 187: 1067–1075. 10.1164/rccm.201210-1913OC <?supplied-pmid 23491408?>23491408 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
